Study of the Predictive Marker FLT in Patients Suffering From AML (TEP-FLT-LMA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01599429|
Recruitment Status : Unknown
Verified September 2014 by Dr Éric E Turcotte, MD, Centre Hospitalier Universitaire de Sherbrooke.
Recruitment status was: Recruiting
First Posted : May 16, 2012
Last Update Posted : September 25, 2014
Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.
Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.
The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.
|Condition or disease|
|Acute Myeloid Leukemia|
|Study Type :||Observational|
|Estimated Enrollment :||24 participants|
|Official Title:||Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||October 2015|
- To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease. [ Time Frame: September 2015 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01599429
|Contact: Annie Morin, MSc||819-346-1110 ext firstname.lastname@example.org|
|Contact: Anick Champoux, Infirmière||819-346-1110 ext email@example.com|
|Centre Hospitalier Universitaire de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Annie Morin, MSc 819-346-1110 ext 16359 firstname.lastname@example.org|
|Contact: Anick Champoux, Infirmière 819-346-1110 ext 12811 email@example.com|
|Sub-Investigator: Hans Knecht, MD|
|Sub-Investigator: Jean-François Castilloux, MD|
|Sub-Investigator: Mariette Lépine, MD|
|Sub-Investigator: Patrice Beauregard, MD|
|Principal Investigator: Rami Kotb, MD|
|Principal Investigator: Éric E Turcotte, MD|
|Principal Investigator:||Éric E Turcotte, MD||Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de recherche Étienne Le-Bel|
|Principal Investigator:||Rami Kotb, MD||Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke|